NiRAN interfering drugs for SARS-CoV-2 mutant therapy

Inventors

Sommadossi, Jean-Pierre • Lin, Kai • Moussa, Adel • Canard, Bruno • Shannon, Ashleigh

Assignees

Atea Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12746251-B2

Patent

Publication Date

2026-09-29

Expiration Date


Abstract

Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12). The invention establishes for the first time herein the foundational discovery of the mechanism of action of the NiRAN-domain, and how it can be used in pharmaceutical therapy against SARS-CoV infection, including a SARS-CoV-2 infection, or exposure.

Core Innovation

The disclosure describes methods of treating or preventing an infection caused by mutant or drug-resistant SARS-CoV-2, including remdesivir-resistant strains, in a human in need thereof. The methods comprise administering an effective amount of a Formula I compound, Compound 1, or related nucleoside phosphoramidate analogs, or a pharmaceutically acceptable salt thereof. These guanosine nucleotide compounds occupy the nsp12 RdRp and NiRAN active sites to inhibit viral RNA synthesis and nsp8 UMPylation.

The disclosed embodiments include phosphoramidate nucleoside analogs across Formulas I through VIII, phosphorus stereoisomers, hemi-sulfate salts, dosage forms, and combination therapies with antiviral agents. Biochemical analyses indicate that the active metabolite AT-9010 terminates viral RNA chain elongation without inducing cytotoxicity or elevated mutation frequencies. In addition, clinical pharmacokinetic evaluations demonstrate dose-related lung exposure meeting predetermined target antiviral levels.

Claims Coverage

The independent claims identify two inventive features directed to methods for treating an infection with a remdesivir-resistant strain of SARS-CoV-2 in a human in need thereof.

Treatment with a Formula I compound

Administering an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to treat an infection with a remdesivir-resistant strain of SARS-CoV-2 virus in a human in need thereof, wherein substituents R1, R2, R3a, R3b, and R4 are defined.

Treatment with Compound 1

Administering an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to treat an infection with a remdesivir-resistant strain of SARS-CoV-2 virus in a human in need thereof.

The independent claims cover methods of treating remdesivir-resistant SARS-CoV-2 infection in humans by administering an effective amount of either defined Formula I compounds or Compound 1, or their pharmaceutically acceptable salts, optionally in a pharmaceutically acceptable carrier.

Stated Advantages

Antiviral activity of Compound 1A is observed against SARS-CoV-1, SARS-CoV-2, and several other human coronaviruses, with weaker activity against MERS-CoV.

In HUH7.5 cells, AT-511 inhibited viral replication without detected cytotoxicity or increased SARS-CoV-2 mutation counts versus virus control.

Targeting the conserved NiRAN pathway provides an antiviral approach that avoids drug-induced mutagenesis and may avoid nsp14-mediated excision to limit resistance development.

Interim clinical pharmacokinetic data report that AT-527 was well tolerated and achieved dose-related lung exposure meeting stated target antiviral levels in lung epithelial lining fluid.

Potential clinical benefits include reduced hospitalization and reduced respiratory failure or death.

Documented Applications

Treatment of an infection caused by a remdesivir-resistant strain of SARS-CoV-2 virus in a human in need thereof using a Formula I compound or Compound 1.

Disruption of coronavirus NiRAN function or treatment or prevention of mutant or drug-resistant SARS-CoV-2 using phosphoramidate nucleoside analogs.

Antiviral combination or alternating therapy with supportive agents for mutant or resistant SARS-CoV infections.

Screening assays and RNA-polymerase assays based on assessing SARS-CoV and SARS-CoV-2 nsp12-mediated nucleotide incorporation, RNA-product effects, and inhibition of NiRAN-mediated nucleotide transfer.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.